Tyme Technologies Inc

Tyme Technologies — Merger or Acquisition (July 2022)

32 slides from Tyme Technologies's merger presentation, Jul 6, 2022

  1. Slide 1: Refinitiv StreetEvents

    REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us ©2022 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing or similar means, is prohibited without the prior written consent of Refinitiv. ‘Refinitiv’ and the Refinitiv logo are registered t

  2. Slide 2: An Expression Makes a World of Difference

    An Expression Makes a World of Difference July 2022 Exhibit 99.2

  3. Slide 3: Forward-looking statements

    Forward-looking statements Forward Looking Statements This presentation contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act concerning Syros, TYME, the proposed transactions and oth

  4. Slide 4: Transaction details: Proposed merger with TYME expected to raise approximately $60 million

    Transaction details: Proposed merger with TYME expected to raise proceeds of approximately $60 million PIPE commitments of $130 million Oxford amendment extends interest only period and maturity date Transactions are expected to close concurrently in 2H 2022, subject to stockholder approval and othe

  5. Slide 5: Advancing our diversified clinical pipeline

    Program Indication Early Clinical IND- Enabling Mid-clinical Pivotal Pivotal Commercial Rights Tamibarotene (oral RARα agonist) Newly diagnosed HR-MDS (w/aza) Newly diagnosed unfit AML (w/ven+aza) SY-2101 (oral ATO) Newly diagnosed APL (w/ATRA) SY-5609 (oral CDK7 inhibitor) Metastatic pancreatic can

  6. Slide 6: Multiple value-driving milestones

    Multiple value-driving milestones Development candidate named from CDK12 program 3Q 2022 SY-5609 SY-2101 in APL Tamibarotene in HR-MDS Tamibarotene in AML Pivotal data from SELECT-MDS-1 Phase 3 trial 4Q23/1Q24 Potential NDA filing 2024 Clinical activity data from safety lead-in SELECT-AML-1 trial 2H

  7. Slide 7: Tamibarotene: Selective oral RARα agonist

    Tamibarotene Selective oral RARα agonist

  8. Slide 8: Value of Tamibarotene

    Value of Tamibarotene Selective and potent RARα agonist; ~50% of MDS patients and ~30% of AML patients are RARA-positive Ongoing Phase 3 trial in newly diagnosed HR-MDS, potentially the first therapy for a targeted population in HR-MDS with broad potential in RARA-positive patients Oral drug with no

  9. Slide 9: High CR rates, rapid onset, and durability in Phase 2 RARA-positive unfit AML

    High CR rates, rapid onset of action, and clinically meaningful durability in Phase 2 trial in RARA-positive newly diagnosed unfit AML 89% of CRs were deep molecular or cytogenetic CRs Responses seen irrespective of mutation or cytogenetic risk Response rates in RARA-negative patients comparable to

  10. Slide 10: Safety profile supports multiple combinations and long-term use

    Safety profile supports multiple combinations and long-term use, enhancing opportunity Generally well-tolerated combination in ND unfit AML patients No increase in neutropenia, anemia and thrombocytopenia compared to single-agent aza Majority of non-hematologic AEs are low grade and reversible aIncl

  11. Slide 11: Ongoing SELECT-MDS-1 Phase 3 trial in RARA-positive newly diagnosed HR-MDS

    Ongoing SELECT-MDS-1 Phase 3 trial in RARA-positive newly diagnosed HR-MDS Robustly designed, double-blind, placebo-controlled study 90% power to detect a difference in CR rates between experimental and control arms 2:1 randomization with one-sided alpha of 0.025 FDA feedback supports: Focus on RARA

  12. Slide 12: Syros' Product Candidate Targets ~50% of HR-MDS patients

    Syros’ Product Candidate Targets ~50% of patients Syros is developing the first in HR-MDS Tamibarotene has the potential to set a new treatment paradigm for RARA-positive HR-MDS patients Physicians are familiar with companion diagnostics to determine optimal treatment for AML à Anticipate rapid adap

  13. Slide 13: Ongoing SELECT-AML-1 Phase 2 trial of triplet regimen

    Randomized portion of trial* ~80 patients Tamibarotene + venetoclax + azacitidine Venetoclax + azacitidine randomization (1:1) Safety lead-In ~15 patients Ongoing SELECT-AML-1 Phase 2 trial of triplet regimen in ND RARA-positive unfit AML patients Also evaluating triplet as salvage strategy for pati

  14. Slide 14: Tamibarotene targets RARA-positive patients, one of the largest targeted populations in unfit AML

    Tamibarotene targets RARA-positive patients which represents one of the largest targeted populations in unfit AML Targeted Populations All Comers Populations ~30% are RARA-positive LDAC + glasdegib HMA1 + venetoclax XOSPATA® (r/r) FLT3+ TIBSOVO ® IDH1+ IDHIFA® IDH2+ Targets ~8% of patients Targets ~

  15. Slide 15: SY-2101: Novel oral form of arsenic trioxide

    SY-2101 Novel oral form of arsenic trioxide

  16. Slide 16: Value of SY-2101

    Novel oral form of arsenic trioxide (ATO) with opportunity to replace standard of care for APL patients; APL is approximately 10% of all AML patients Orally bioavailable with exposures consistent with IV ATO Clear development path to approval in front-line APL Potential for rapid adoption in front-l

  17. Slide 17: Clear development path in front-line APL

    Clear development path in front-line APL Dose confirmation study evaluating PK and food effect using Cmax and AUC, and tolerability to identify optimal dose for Phase 3 trial FDA feedback from November 2021 supports: Molecular CR as primary endpoint compared to historic data for accelerated approval

  18. Slide 18: SY-2101 offers opportunity to reduce treatment burden and health care costs

    SY-2101 offers significant opportunity to reduce treatment burden, increase access, reduce health care costs and utilization Current standard of care IV ATO oral ATRA >80% Cure rates Treatment burden: Current course of treatment involves infusions of Market opportunity for an oral therapy: APL accou

  19. Slide 19: SY-5609: Highly selective and potent oral CDK7 inhibitor

    SY-5609 Highly selective and potent oral CDK7 inhibitor

  20. Slide 20: SY-5609: Highly selective and potent oral CDK7 inhibitor

    Cell Cycle SY-5609: Highly selective and potent oral CDK7 inhibitor SY-5609 is highly selective with subnanomolar potency1 1Marineau JJ et al, 2021, Discovery of SY-5609: A Selective, Noncovalent Inhibitor of CDK7, J Med Chem Data presented in October 2019 at EORTC-NCI-AACR Conference Transcription

  21. Slide 21: Tolerability optimized with 7d on/7d off dosing schedule

    Tolerability was optimized with 7d on/7d off dosing schedule Phase 1 dose escalation study: Favorable tolerability profile with predominantly low-grade AEs Data presented at ESMO 2021; data cutoff July 6, 2021 Manageable safety profile with majority of AEs low-grade and reversible Low rate of discon

  22. Slide 22: Clinical activity in heavily pretreated patients; strongest in PDAC, Rb-altered and KRAS-mutant cancers

    Clinical activity seen in heavily pretreated patients; strongest in PDAC, Rb-altered and KRAS-mutant cancers Data presented at ESMO 2021 1Internal company data Highest rates of activity seen in pancreatic cancer patients and Rb-altered tumor cohort1 *Rb-altered patients had tumor types other than br

  23. Slide 23: Exploring SY-5609 in two distinct approaches

    Exploring SY-5609 in two distinct approaches based on mechanistic rationale, preclinical data and clinical signals Pancreatic Cancer KRAS mutations are ubiquitous and powerful activators of cell signaling and transcriptional programs Compelling preclinical data and synergy with gemcitabine Single ag

  24. Slide 24: Ongoing safety lead-in in relapsed pancreatic patients

    Ongoing safety lead-in portion of the Phase 1 trial in relapsed pancreatic patients Safety lead-in portion of the trial will be evaluating: Safety Tolerability Signs of clinical activity Safety lead-in Doublet with gemcitabine Triplet with gemcitabine and nab-paclitaxel Safety lead-in 1Sadhu and Vin

  25. Slide 25: Preclinical data support SY-5609 in BRAF-mutant CRC with PDL1 inhibitor

    Preclinical data support SY-5609 in BRAF-mutant CRC in combination with PDL1 inhibitor: SY-5609 part of Roche’s Phase 1/1b INTRINSIC trial 67% (20/30) of models demonstrated ≥ 50% TGI 23% (7/30) demonstrated deep responses of ≥ 90% TGI Deep responses enriched in BRAF-mutant (5/10) models Robust anti

  26. Slide 26: Gene Control Discovery Engine

    Gene Control Discovery Engine

  27. Slide 27: Regulatory regions of the genome control gene expression

    Previously unexplored regulatory regions of the genome control expression of genes determining cell function; majority of disease variation found in these regions 98% Patient Impact Medicines that control the expression of genes to provide profound benefit for patients with severe diseases Redefinin

  28. Slide 28: Partnered and oncology discovery programs

    PARTNERED PROGRAMS Program Target Development Drug Discovery IND-enabling Commercial Rights Sickle cell disease & beta thalassemia Myeloproliferative neoplasms Seeking partnerships for our oncology discovery programs ONCOLOGY Program Target Development Drug Discovery IND-enabling Commercial Rights C

  29. Slide 29: Rapidly advancing toward our vision

    Rapidly advancing toward our vision Preparing for product launches Commercial company with medicines that provide a profound benefit for cancer patients Advancing late-stage targeted hematology pipeline Expected capital to fund planned operations into 2025 Now Next Vision

  30. Slide 30: Appendix

    Appendix SYR":S

  31. Slide 31: Preclinical data support SY-5609 in relapsed pancreatic cancer with chemotherapy

    Preclinical data support SY-5609 in relapsed pancreatic cancer patients in combination with chemotherapy SY-5609 potentiated activity of gemcitibine in pancreatic cancer model using 7d on/7d off regimen Vehicle SY-5609: 3mg/kg, P.O., QD 7/7 Gemcitabine: 50mg/kg, I.P., BIW Combination: Same doses and

  32. Slide 32: SYR2:S

    SYR2:S

Tyme Technologies — Merger or Acquisition (July 2022) on 6ix